nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—BMPR1B—prostate cancer	0.138	0.323	CbGaD
Crizotinib—AURKA—Epirubicin—prostate cancer	0.0808	0.345	CbGbCtD
Crizotinib—AURKA—prostate cancer	0.0754	0.177	CbGaD
Crizotinib—IGF1R—prostate cancer	0.0696	0.163	CbGaD
Crizotinib—JAK2—prostate cancer	0.0672	0.158	CbGaD
Crizotinib—AURKA—Doxorubicin—prostate cancer	0.0429	0.183	CbGbCtD
Crizotinib—SRC—prostate cancer	0.0421	0.0989	CbGaD
Crizotinib—CYP3A5—prostate cancer	0.0239	0.0561	CbGaD
Crizotinib—CYP3A4—prostate cancer	0.0103	0.0243	CbGaD
Crizotinib—CYP3A5—Flutamide—prostate cancer	0.00969	0.0414	CbGbCtD
Crizotinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00868	0.0371	CbGbCtD
Crizotinib—CYP3A5—Cabazitaxel—prostate cancer	0.00717	0.0306	CbGbCtD
Crizotinib—ABCB1—Estramustine—prostate cancer	0.00707	0.0302	CbGbCtD
Crizotinib—CYP3A5—Estrone—prostate cancer	0.007	0.0299	CbGbCtD
Crizotinib—ABCB1—Cabazitaxel—prostate cancer	0.00466	0.0199	CbGbCtD
Crizotinib—CYP3A4—Bicalutamide—prostate cancer	0.00456	0.0195	CbGbCtD
Crizotinib—ABCB1—Estrone—prostate cancer	0.00456	0.0195	CbGbCtD
Crizotinib—CYP3A4—Estramustine—prostate cancer	0.00424	0.0181	CbGbCtD
Crizotinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00406	0.0174	CbGbCtD
Crizotinib—CYP3A5—Estradiol—prostate cancer	0.00402	0.0172	CbGbCtD
Crizotinib—CYP3A4—Abiraterone—prostate cancer	0.00378	0.0161	CbGbCtD
Crizotinib—CYP3A4—Flutamide—prostate cancer	0.00378	0.0161	CbGbCtD
Crizotinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00298	0.0127	CbGbCtD
Crizotinib—CYP3A4—Cabazitaxel—prostate cancer	0.00279	0.0119	CbGbCtD
Crizotinib—CYP3A4—Estrone—prostate cancer	0.00273	0.0117	CbGbCtD
Crizotinib—ABCB1—Mitoxantrone—prostate cancer	0.00271	0.0116	CbGbCtD
Crizotinib—CYP3A5—Etoposide—prostate cancer	0.00263	0.0112	CbGbCtD
Crizotinib—ABCB1—Estradiol—prostate cancer	0.00262	0.0112	CbGbCtD
Crizotinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00243	0.0104	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—prostate cancer	0.0024	0.0103	CbGbCtD
Crizotinib—ABCB1—Prednisone—prostate cancer	0.00225	0.00962	CbGbCtD
Crizotinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00179	0.00764	CbGbCtD
Crizotinib—ABCB1—Etoposide—prostate cancer	0.00171	0.00731	CbGbCtD
Crizotinib—CYP3A4—Mitoxantrone—prostate cancer	0.00162	0.00694	CbGbCtD
Crizotinib—CYP3A4—Estradiol—prostate cancer	0.00157	0.00671	CbGbCtD
Crizotinib—ABCB1—Docetaxel—prostate cancer	0.00156	0.00669	CbGbCtD
Crizotinib—CYP3A4—Prednisone—prostate cancer	0.00135	0.00577	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—prostate cancer	0.00117	0.00498	CbGbCtD
Crizotinib—CYP3A4—Etoposide—prostate cancer	0.00102	0.00438	CbGbCtD
Crizotinib—CYP3A4—Docetaxel—prostate cancer	0.000937	0.00401	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—prostate cancer	0.000699	0.00299	CbGbCtD
Crizotinib—TIE1—urethra—prostate cancer	0.00029	0.00343	CbGeAlD
Crizotinib—PRKD3—testis—prostate cancer	0.000289	0.00342	CbGeAlD
Crizotinib—TEK—prostate gland—prostate cancer	0.000288	0.00341	CbGeAlD
Crizotinib—MAP3K3—prostate gland—prostate cancer	0.000288	0.00341	CbGeAlD
Crizotinib—MAP4K5—prostate gland—prostate cancer	0.000288	0.00341	CbGeAlD
Crizotinib—AURKA—renal system—prostate cancer	0.000288	0.00341	CbGeAlD
Crizotinib—TESK1—renal system—prostate cancer	0.000286	0.00338	CbGeAlD
Crizotinib—DSTYK—testis—prostate cancer	0.000282	0.00333	CbGeAlD
Crizotinib—TESK1—urethra—prostate cancer	0.000281	0.00332	CbGeAlD
Crizotinib—PTK2—seminal vesicle—prostate cancer	0.00028	0.00331	CbGeAlD
Crizotinib—TBK1—seminal vesicle—prostate cancer	0.00028	0.00331	CbGeAlD
Crizotinib—TYK2—seminal vesicle—prostate cancer	0.000278	0.00329	CbGeAlD
Crizotinib—LTK—testis—prostate cancer	0.000276	0.00326	CbGeAlD
Crizotinib—CASK—testis—prostate cancer	0.000276	0.00326	CbGeAlD
Crizotinib—EPHB6—prostate gland—prostate cancer	0.000275	0.00326	CbGeAlD
Crizotinib—MERTK—urethra—prostate cancer	0.000273	0.00323	CbGeAlD
Crizotinib—RPS6KB1—seminal vesicle—prostate cancer	0.000269	0.00318	CbGeAlD
Crizotinib—ACVR1—renal system—prostate cancer	0.000269	0.00318	CbGeAlD
Crizotinib—FGR—seminal vesicle—prostate cancer	0.000268	0.00316	CbGeAlD
Crizotinib—MAPK7—testis—prostate cancer	0.000267	0.00316	CbGeAlD
Crizotinib—TXK—testis—prostate cancer	0.000267	0.00316	CbGeAlD
Crizotinib—YES1—prostate gland—prostate cancer	0.000266	0.00315	CbGeAlD
Crizotinib—EPHA8—testis—prostate cancer	0.000264	0.00312	CbGeAlD
Crizotinib—FES—testis—prostate cancer	0.000264	0.00312	CbGeAlD
Crizotinib—ACVR1—urethra—prostate cancer	0.000264	0.00312	CbGeAlD
Crizotinib—MAP3K12—urethra—prostate cancer	0.000264	0.00312	CbGeAlD
Crizotinib—STK10—prostate gland—prostate cancer	0.000264	0.00312	CbGeAlD
Crizotinib—TAOK3—prostate gland—prostate cancer	0.000263	0.00311	CbGeAlD
Crizotinib—RIPK2—epithelium—prostate cancer	0.000262	0.0031	CbGeAlD
Crizotinib—SLK—seminal vesicle—prostate cancer	0.000257	0.00303	CbGeAlD
Crizotinib—SRC—prostate gland—prostate cancer	0.000256	0.00303	CbGeAlD
Crizotinib—EPHB4—seminal vesicle—prostate cancer	0.000255	0.00301	CbGeAlD
Crizotinib—PLK4—bone marrow—prostate cancer	0.000255	0.00301	CbGeAlD
Crizotinib—JAK2—seminal vesicle—prostate cancer	0.000253	0.00299	CbGeAlD
Crizotinib—MET—testis—prostate cancer	0.00025	0.00295	CbGeAlD
Crizotinib—EPHA2—seminal vesicle—prostate cancer	0.00025	0.00295	CbGeAlD
Crizotinib—PTK2B—renal system—prostate cancer	0.000245	0.0029	CbGeAlD
Crizotinib—MAP3K3—seminal vesicle—prostate cancer	0.000244	0.00288	CbGeAlD
Crizotinib—MAP4K5—seminal vesicle—prostate cancer	0.000244	0.00288	CbGeAlD
Crizotinib—PTK2—epithelium—prostate cancer	0.000243	0.00287	CbGeAlD
Crizotinib—CDK7—testis—prostate cancer	0.000242	0.00286	CbGeAlD
Crizotinib—TAOK2—testis—prostate cancer	0.00024	0.00284	CbGeAlD
Crizotinib—NEK9—lymph node—prostate cancer	0.000239	0.00283	CbGeAlD
Crizotinib—RIPK2—urethra—prostate cancer	0.000239	0.00282	CbGeAlD
Crizotinib—MAP4K1—bone marrow—prostate cancer	0.000234	0.00277	CbGeAlD
Crizotinib—RPS6KB1—epithelium—prostate cancer	0.000234	0.00277	CbGeAlD
Crizotinib—EPHB6—seminal vesicle—prostate cancer	0.000233	0.00275	CbGeAlD
Crizotinib—EPHA3—testis—prostate cancer	0.000231	0.00273	CbGeAlD
Crizotinib—ACVR1B—testis—prostate cancer	0.000231	0.00273	CbGeAlD
Crizotinib—EPHA4—urethra—prostate cancer	0.000231	0.00273	CbGeAlD
Crizotinib—CSF1R—prostate gland—prostate cancer	0.00023	0.00272	CbGeAlD
Crizotinib—MAP4K2—bone marrow—prostate cancer	0.000227	0.00268	CbGeAlD
Crizotinib—PTK2—renal system—prostate cancer	0.000226	0.00267	CbGeAlD
Crizotinib—TBK1—renal system—prostate cancer	0.000226	0.00267	CbGeAlD
Crizotinib—YES1—seminal vesicle—prostate cancer	0.000225	0.00266	CbGeAlD
Crizotinib—TYK2—renal system—prostate cancer	0.000224	0.00265	CbGeAlD
Crizotinib—CYP3A4—urine—prostate cancer	0.000222	0.00263	CbGeAlD
Crizotinib—TAOK3—seminal vesicle—prostate cancer	0.000222	0.00263	CbGeAlD
Crizotinib—TBK1—urethra—prostate cancer	0.000222	0.00262	CbGeAlD
Crizotinib—PTK2—urethra—prostate cancer	0.000222	0.00262	CbGeAlD
Crizotinib—EPHB4—epithelium—prostate cancer	0.000221	0.00262	CbGeAlD
Crizotinib—EPHA6—testis—prostate cancer	0.00022	0.00261	CbGeAlD
Crizotinib—JAK3—testis—prostate cancer	0.00022	0.00261	CbGeAlD
Crizotinib—TYK2—urethra—prostate cancer	0.00022	0.0026	CbGeAlD
Crizotinib—JAK2—epithelium—prostate cancer	0.00022	0.0026	CbGeAlD
Crizotinib—DCLK1—testis—prostate cancer	0.000219	0.00259	CbGeAlD
Crizotinib—PRKD1—lymph node—prostate cancer	0.000218	0.00258	CbGeAlD
Crizotinib—AURKA—bone marrow—prostate cancer	0.000218	0.00258	CbGeAlD
Crizotinib—PLK4—testis—prostate cancer	0.000218	0.00257	CbGeAlD
Crizotinib—EPHA2—epithelium—prostate cancer	0.000217	0.00257	CbGeAlD
Crizotinib—RPS6KB1—renal system—prostate cancer	0.000217	0.00257	CbGeAlD
Crizotinib—STK4—testis—prostate cancer	0.000216	0.00256	CbGeAlD
Crizotinib—LIMK1—lymph node—prostate cancer	0.000215	0.00254	CbGeAlD
Crizotinib—RPS6KB1—urethra—prostate cancer	0.000213	0.00252	CbGeAlD
Crizotinib—FGR—urethra—prostate cancer	0.000212	0.0025	CbGeAlD
Crizotinib—LCK—urethra—prostate cancer	0.000212	0.0025	CbGeAlD
Crizotinib—TEK—epithelium—prostate cancer	0.000212	0.0025	CbGeAlD
Crizotinib—AXL—urethra—prostate cancer	0.000211	0.00249	CbGeAlD
Crizotinib—MERTK—bone marrow—prostate cancer	0.00021	0.00248	CbGeAlD
Crizotinib—PRKD3—lymph node—prostate cancer	0.000209	0.00248	CbGeAlD
Crizotinib—EPHB4—renal system—prostate cancer	0.000205	0.00243	CbGeAlD
Crizotinib—NUAK2—bone marrow—prostate cancer	0.000205	0.00242	CbGeAlD
Crizotinib—FER—testis—prostate cancer	0.000204	0.00242	CbGeAlD
Crizotinib—TYRO3—testis—prostate cancer	0.000204	0.00242	CbGeAlD
Crizotinib—ALK—testis—prostate cancer	0.000204	0.00242	CbGeAlD
Crizotinib—DSTYK—lymph node—prostate cancer	0.000204	0.00242	CbGeAlD
Crizotinib—JAK2—renal system—prostate cancer	0.000204	0.00241	CbGeAlD
Crizotinib—FLT3—bone marrow—prostate cancer	0.000203	0.0024	CbGeAlD
Crizotinib—ACVR1—bone marrow—prostate cancer	0.000203	0.0024	CbGeAlD
Crizotinib—SLK—urethra—prostate cancer	0.000203	0.0024	CbGeAlD
Crizotinib—TNK1—testis—prostate cancer	0.000202	0.00239	CbGeAlD
Crizotinib—BLK—lymph node—prostate cancer	0.000202	0.00239	CbGeAlD
Crizotinib—EPHB4—urethra—prostate cancer	0.000202	0.00238	CbGeAlD
Crizotinib—MAP3K19—testis—prostate cancer	0.0002	0.00237	CbGeAlD
Crizotinib—BMPR1B—testis—prostate cancer	0.0002	0.00237	CbGeAlD
Crizotinib—MAP4K1—testis—prostate cancer	0.0002	0.00237	CbGeAlD
Crizotinib—JAK2—urethra—prostate cancer	0.0002	0.00237	CbGeAlD
Crizotinib—LTK—lymph node—prostate cancer	0.0002	0.00236	CbGeAlD
Crizotinib—CASK—lymph node—prostate cancer	0.0002	0.00236	CbGeAlD
Crizotinib—EPHA2—urethra—prostate cancer	0.000198	0.00234	CbGeAlD
Crizotinib—TEK—renal system—prostate cancer	0.000196	0.00232	CbGeAlD
Crizotinib—TNK2—testis—prostate cancer	0.000196	0.00232	CbGeAlD
Crizotinib—IGF1R—testis—prostate cancer	0.000196	0.00232	CbGeAlD
Crizotinib—CSF1R—seminal vesicle—prostate cancer	0.000194	0.0023	CbGeAlD
Crizotinib—MAP4K2—testis—prostate cancer	0.000194	0.00229	CbGeAlD
Crizotinib—MAPK7—lymph node—prostate cancer	0.000193	0.00229	CbGeAlD
Crizotinib—TXK—lymph node—prostate cancer	0.000193	0.00229	CbGeAlD
Crizotinib—MAP4K5—urethra—prostate cancer	0.000193	0.00228	CbGeAlD
Crizotinib—MAP3K3—urethra—prostate cancer	0.000193	0.00228	CbGeAlD
Crizotinib—TEK—urethra—prostate cancer	0.000193	0.00228	CbGeAlD
Crizotinib—BMP2K—bone marrow—prostate cancer	0.000192	0.00227	CbGeAlD
Crizotinib—FES—lymph node—prostate cancer	0.000192	0.00226	CbGeAlD
Crizotinib—STK3—testis—prostate cancer	0.000191	0.00226	CbGeAlD
Crizotinib—TIE1—testis—prostate cancer	0.000191	0.00226	CbGeAlD
Crizotinib—SRC—epithelium—prostate cancer	0.000188	0.00222	CbGeAlD
Crizotinib—AURKA—testis—prostate cancer	0.000186	0.0022	CbGeAlD
Crizotinib—PTK2B—bone marrow—prostate cancer	0.000185	0.00219	CbGeAlD
Crizotinib—TESK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000185	0.0711	CbGdCrCtD
Crizotinib—TESK1—testis—prostate cancer	0.000185	0.00218	CbGeAlD
Crizotinib—EPHB6—urethra—prostate cancer	0.000184	0.00218	CbGeAlD
Crizotinib—RIPK2—bone marrow—prostate cancer	0.000184	0.00217	CbGeAlD
Crizotinib—ABL1—prostate gland—prostate cancer	0.000182	0.00215	CbGeAlD
Crizotinib—YES1—renal system—prostate cancer	0.000181	0.00215	CbGeAlD
Crizotinib—MET—lymph node—prostate cancer	0.000181	0.00214	CbGeAlD
Crizotinib—STK10—renal system—prostate cancer	0.00018	0.00213	CbGeAlD
Crizotinib—MERTK—testis—prostate cancer	0.00018	0.00212	CbGeAlD
Crizotinib—TAOK3—renal system—prostate cancer	0.000179	0.00212	CbGeAlD
Crizotinib—YES1—urethra—prostate cancer	0.000178	0.00211	CbGeAlD
Crizotinib—TAOK3—urethra—prostate cancer	0.000176	0.00208	CbGeAlD
Crizotinib—LIMK2—testis—prostate cancer	0.000176	0.00208	CbGeAlD
Crizotinib—CDK7—lymph node—prostate cancer	0.000175	0.00207	CbGeAlD
Crizotinib—NUAK2—testis—prostate cancer	0.000175	0.00207	CbGeAlD
Crizotinib—SRC—renal system—prostate cancer	0.000175	0.00206	CbGeAlD
Crizotinib—MAP3K2—bone marrow—prostate cancer	0.000174	0.00206	CbGeAlD
Crizotinib—MAP3K12—testis—prostate cancer	0.000174	0.00206	CbGeAlD
Crizotinib—FLT3—testis—prostate cancer	0.000174	0.00206	CbGeAlD
Crizotinib—ACVR1—testis—prostate cancer	0.000174	0.00206	CbGeAlD
Crizotinib—TAOK2—lymph node—prostate cancer	0.000174	0.00206	CbGeAlD
Crizotinib—IGF1R—Fulvestrant—Estradiol—prostate cancer	0.000174	0.0668	CbGdCrCtD
Crizotinib—TBK1—bone marrow—prostate cancer	0.000171	0.00202	CbGeAlD
Crizotinib—STK35—testis—prostate cancer	0.00017	0.00201	CbGeAlD
Crizotinib—TYK2—bone marrow—prostate cancer	0.000169	0.002	CbGeAlD
Crizotinib—EPHA3—lymph node—prostate cancer	0.000167	0.00198	CbGeAlD
Crizotinib—ACVR1B—lymph node—prostate cancer	0.000167	0.00198	CbGeAlD
Crizotinib—IRAK1—bone marrow—prostate cancer	0.000167	0.00198	CbGeAlD
Crizotinib—ABL2—testis—prostate cancer	0.000166	0.00196	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—prostate cancer	0.000164	0.00194	CbGeAlD
Crizotinib—BMP2K—testis—prostate cancer	0.000164	0.00194	CbGeAlD
Crizotinib—LCK—bone marrow—prostate cancer	0.000163	0.00193	CbGeAlD
Crizotinib—FGR—bone marrow—prostate cancer	0.000163	0.00193	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—prostate cancer	0.000163	0.0625	CbGdCrCtD
Crizotinib—JAK3—lymph node—prostate cancer	0.00016	0.00189	CbGeAlD
Crizotinib—DCLK1—lymph node—prostate cancer	0.000159	0.00188	CbGeAlD
Crizotinib—PTK2B—testis—prostate cancer	0.000158	0.00187	CbGeAlD
Crizotinib—PLK4—lymph node—prostate cancer	0.000158	0.00187	CbGeAlD
Crizotinib—TESK1—Estradiol—Estramustine—prostate cancer	0.000157	0.0605	CbGdCrCtD
Crizotinib—RIPK2—testis—prostate cancer	0.000157	0.00186	CbGeAlD
Crizotinib—STK4—lymph node—prostate cancer	0.000157	0.00185	CbGeAlD
Crizotinib—SLK—bone marrow—prostate cancer	0.000156	0.00185	CbGeAlD
Crizotinib—EPHB4—bone marrow—prostate cancer	0.000155	0.00183	CbGeAlD
Crizotinib—JAK2—bone marrow—prostate cancer	0.000154	0.00182	CbGeAlD
Crizotinib—CSF1R—urethra—prostate cancer	0.000154	0.00182	CbGeAlD
Crizotinib—ABL1—seminal vesicle—prostate cancer	0.000154	0.00182	CbGeAlD
Crizotinib—EPHA4—testis—prostate cancer	0.000152	0.00179	CbGeAlD
Crizotinib—MAP3K2—testis—prostate cancer	0.000149	0.00176	CbGeAlD
Crizotinib—MAP4K5—bone marrow—prostate cancer	0.000149	0.00176	CbGeAlD
Crizotinib—MAP3K3—bone marrow—prostate cancer	0.000149	0.00176	CbGeAlD
Crizotinib—FER—lymph node—prostate cancer	0.000148	0.00175	CbGeAlD
Crizotinib—ALK—lymph node—prostate cancer	0.000148	0.00175	CbGeAlD
Crizotinib—TNK1—lymph node—prostate cancer	0.000147	0.00173	CbGeAlD
Crizotinib—TBK1—testis—prostate cancer	0.000146	0.00172	CbGeAlD
Crizotinib—PTK2—testis—prostate cancer	0.000146	0.00172	CbGeAlD
Crizotinib—BMPR1B—lymph node—prostate cancer	0.000145	0.00172	CbGeAlD
Crizotinib—MAP4K1—lymph node—prostate cancer	0.000145	0.00172	CbGeAlD
Crizotinib—TYK2—testis—prostate cancer	0.000145	0.00171	CbGeAlD
Crizotinib—IRAK1—testis—prostate cancer	0.000143	0.00169	CbGeAlD
Crizotinib—IGF1R—lymph node—prostate cancer	0.000142	0.00168	CbGeAlD
Crizotinib—TNK2—lymph node—prostate cancer	0.000142	0.00168	CbGeAlD
Crizotinib—MAP4K2—lymph node—prostate cancer	0.00014	0.00166	CbGeAlD
Crizotinib—RPS6KB1—testis—prostate cancer	0.00014	0.00166	CbGeAlD
Crizotinib—FGR—testis—prostate cancer	0.000139	0.00165	CbGeAlD
Crizotinib—LCK—testis—prostate cancer	0.000139	0.00165	CbGeAlD
Crizotinib—AXL—testis—prostate cancer	0.000139	0.00164	CbGeAlD
Crizotinib—TIE1—lymph node—prostate cancer	0.000138	0.00164	CbGeAlD
Crizotinib—STK3—lymph node—prostate cancer	0.000138	0.00164	CbGeAlD
Crizotinib—YES1—bone marrow—prostate cancer	0.000137	0.00162	CbGeAlD
Crizotinib—STK10—bone marrow—prostate cancer	0.000136	0.00161	CbGeAlD
Crizotinib—TAOK3—bone marrow—prostate cancer	0.000135	0.0016	CbGeAlD
Crizotinib—AURKA—lymph node—prostate cancer	0.000135	0.0016	CbGeAlD
Crizotinib—TESK1—lymph node—prostate cancer	0.000134	0.00158	CbGeAlD
Crizotinib—SLK—testis—prostate cancer	0.000134	0.00158	CbGeAlD
Crizotinib—EPHB4—testis—prostate cancer	0.000133	0.00157	CbGeAlD
Crizotinib—JAK2—testis—prostate cancer	0.000132	0.00156	CbGeAlD
Crizotinib—MERTK—lymph node—prostate cancer	0.00013	0.00154	CbGeAlD
Crizotinib—EPHA2—testis—prostate cancer	0.00013	0.00154	CbGeAlD
Crizotinib—LIMK2—lymph node—prostate cancer	0.000127	0.00151	CbGeAlD
Crizotinib—TEK—testis—prostate cancer	0.000127	0.0015	CbGeAlD
Crizotinib—MAP4K5—testis—prostate cancer	0.000127	0.0015	CbGeAlD
Crizotinib—MAP3K3—testis—prostate cancer	0.000127	0.0015	CbGeAlD
Crizotinib—NUAK2—lymph node—prostate cancer	0.000127	0.0015	CbGeAlD
Crizotinib—MAP3K12—lymph node—prostate cancer	0.000126	0.00149	CbGeAlD
Crizotinib—FLT3—lymph node—prostate cancer	0.000126	0.00149	CbGeAlD
Crizotinib—ACVR1—lymph node—prostate cancer	0.000126	0.00149	CbGeAlD
Crizotinib—TESK1—Estradiol—Estrone—prostate cancer	0.000125	0.0481	CbGdCrCtD
Crizotinib—ABL1—renal system—prostate cancer	0.000124	0.00146	CbGeAlD
Crizotinib—STK35—lymph node—prostate cancer	0.000123	0.00146	CbGeAlD
Crizotinib—ABL1—urethra—prostate cancer	0.000122	0.00144	CbGeAlD
Crizotinib—EPHB6—testis—prostate cancer	0.000121	0.00143	CbGeAlD
Crizotinib—ABL2—lymph node—prostate cancer	0.00012	0.00142	CbGeAlD
Crizotinib—BMP2K—lymph node—prostate cancer	0.000119	0.0014	CbGeAlD
Crizotinib—CSF1R—bone marrow—prostate cancer	0.000118	0.0014	CbGeAlD
Crizotinib—YES1—testis—prostate cancer	0.000117	0.00139	CbGeAlD
Crizotinib—STK10—testis—prostate cancer	0.000116	0.00137	CbGeAlD
Crizotinib—TAOK3—testis—prostate cancer	0.000116	0.00137	CbGeAlD
Crizotinib—PTK2B—lymph node—prostate cancer	0.000115	0.00136	CbGeAlD
Crizotinib—RIPK2—lymph node—prostate cancer	0.000114	0.00135	CbGeAlD
Crizotinib—SRC—testis—prostate cancer	0.000113	0.00133	CbGeAlD
Crizotinib—TESK1—Estradiol—Conjugated Estrogens—prostate cancer	0.00011	0.0423	CbGdCrCtD
Crizotinib—EPHA4—lymph node—prostate cancer	0.00011	0.0013	CbGeAlD
Crizotinib—MAP3K2—lymph node—prostate cancer	0.000108	0.00128	CbGeAlD
Crizotinib—CYP3A5—prostate gland—prostate cancer	0.000106	0.00126	CbGeAlD
Crizotinib—PTK2—lymph node—prostate cancer	0.000106	0.00125	CbGeAlD
Crizotinib—TBK1—lymph node—prostate cancer	0.000106	0.00125	CbGeAlD
Crizotinib—TYK2—lymph node—prostate cancer	0.000105	0.00124	CbGeAlD
Crizotinib—IRAK1—lymph node—prostate cancer	0.000104	0.00122	CbGeAlD
Crizotinib—RPS6KB1—lymph node—prostate cancer	0.000102	0.0012	CbGeAlD
Crizotinib—CSF1R—testis—prostate cancer	0.000101	0.0012	CbGeAlD
Crizotinib—LCK—lymph node—prostate cancer	0.000101	0.00119	CbGeAlD
Crizotinib—FGR—lymph node—prostate cancer	0.000101	0.00119	CbGeAlD
Crizotinib—AXL—lymph node—prostate cancer	0.000101	0.00119	CbGeAlD
Crizotinib—SLK—lymph node—prostate cancer	9.68e-05	0.00115	CbGeAlD
Crizotinib—EPHB4—lymph node—prostate cancer	9.62e-05	0.00114	CbGeAlD
Crizotinib—JAK2—lymph node—prostate cancer	9.55e-05	0.00113	CbGeAlD
Crizotinib—EPHA2—lymph node—prostate cancer	9.43e-05	0.00112	CbGeAlD
Crizotinib—ABL1—bone marrow—prostate cancer	9.36e-05	0.00111	CbGeAlD
Crizotinib—TESK1—Estradiol—Ethinyl Estradiol—prostate cancer	9.24e-05	0.0355	CbGdCrCtD
Crizotinib—MAP3K3—lymph node—prostate cancer	9.2e-05	0.00109	CbGeAlD
Crizotinib—TEK—lymph node—prostate cancer	9.2e-05	0.00109	CbGeAlD
Crizotinib—MAP4K5—lymph node—prostate cancer	9.2e-05	0.00109	CbGeAlD
Crizotinib—PLK4—Fulvestrant—Estradiol—prostate cancer	9.12e-05	0.0351	CbGdCrCtD
Crizotinib—EPHB6—lymph node—prostate cancer	8.79e-05	0.00104	CbGeAlD
Crizotinib—YES1—lymph node—prostate cancer	8.5e-05	0.001	CbGeAlD
Crizotinib—STK10—lymph node—prostate cancer	8.42e-05	0.000996	CbGeAlD
Crizotinib—TAOK3—lymph node—prostate cancer	8.39e-05	0.000992	CbGeAlD
Crizotinib—SRC—lymph node—prostate cancer	8.18e-05	0.000967	CbGeAlD
Crizotinib—PLK4—Teniposide—Etoposide—prostate cancer	8.03e-05	0.0309	CbGdCrCtD
Crizotinib—ABL1—testis—prostate cancer	8e-05	0.000946	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Epirubicin—prostate cancer	7.97e-05	0.0307	CbGdCrCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—prostate cancer	7.38e-05	0.0284	CbGdCrCtD
Crizotinib—CSF1R—lymph node—prostate cancer	7.34e-05	0.000868	CbGeAlD
Crizotinib—CYP3A5—renal system—prostate cancer	7.25e-05	0.000857	CbGeAlD
Crizotinib—AURKA—Fulvestrant—Estradiol—prostate cancer	7.14e-05	0.0275	CbGdCrCtD
Crizotinib—ABL1—Levorphanol—Estrone—prostate cancer	6.69e-05	0.0257	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—prostate cancer	6.43e-05	0.0247	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—prostate cancer	6.43e-05	0.0247	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—prostate cancer	6.43e-05	0.0247	CbGdCrCtD
Crizotinib—AURKA—Teniposide—Etoposide—prostate cancer	6.29e-05	0.0242	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—prostate cancer	5.95e-05	0.0229	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—prostate cancer	5.95e-05	0.0229	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—prostate cancer	5.95e-05	0.0229	CbGdCrCtD
Crizotinib—Diarrhoea—Goserelin—prostate cancer	5.82e-05	0.000554	CcSEcCtD
Crizotinib—Fatigue—Estradiol—prostate cancer	5.81e-05	0.000553	CcSEcCtD
Crizotinib—Urethral disorder—Capecitabine—prostate cancer	5.8e-05	0.000552	CcSEcCtD
Crizotinib—ABL1—lymph node—prostate cancer	5.8e-05	0.000686	CbGeAlD
Crizotinib—Constipation—Estradiol—prostate cancer	5.77e-05	0.000549	CcSEcCtD
Crizotinib—Diarrhoea—Conjugated Estrogens—prostate cancer	5.77e-05	0.000549	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—prostate cancer	5.76e-05	0.000548	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—prostate cancer	5.76e-05	0.000548	CcSEcCtD
Crizotinib—Leukopenia—Etoposide—prostate cancer	5.73e-05	0.000546	CcSEcCtD
Crizotinib—Eye disorder—Docetaxel—prostate cancer	5.71e-05	0.000544	CcSEcCtD
Crizotinib—Visual impairment—Capecitabine—prostate cancer	5.7e-05	0.000543	CcSEcCtD
Crizotinib—Cardiac disorder—Docetaxel—prostate cancer	5.67e-05	0.00054	CcSEcCtD
Crizotinib—ABCB1—prostate gland—prostate cancer	5.65e-05	0.000668	CbGeAlD
Crizotinib—Paraesthesia—Mitoxantrone—prostate cancer	5.64e-05	0.000537	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—prostate cancer	5.63e-05	0.000536	CcSEcCtD
Crizotinib—Dizziness—Goserelin—prostate cancer	5.63e-05	0.000535	CcSEcCtD
Crizotinib—Dyspnoea—Mitoxantrone—prostate cancer	5.6e-05	0.000533	CcSEcCtD
Crizotinib—Dizziness—Conjugated Estrogens—prostate cancer	5.57e-05	0.00053	CcSEcCtD
Crizotinib—Eye disorder—Capecitabine—prostate cancer	5.53e-05	0.000527	CcSEcCtD
Crizotinib—Dyspepsia—Mitoxantrone—prostate cancer	5.53e-05	0.000527	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—prostate cancer	5.52e-05	0.000525	CcSEcCtD
Crizotinib—Mediastinal disorder—Docetaxel—prostate cancer	5.51e-05	0.000525	CcSEcCtD
Crizotinib—Cardiac disorder—Capecitabine—prostate cancer	5.49e-05	0.000523	CcSEcCtD
Crizotinib—Decreased appetite—Mitoxantrone—prostate cancer	5.46e-05	0.00052	CcSEcCtD
Crizotinib—Arrhythmia—Docetaxel—prostate cancer	5.46e-05	0.00052	CcSEcCtD
Crizotinib—CYP3A4—renal system—prostate cancer	5.44e-05	0.000643	CbGeAlD
Crizotinib—Hypokalaemia—Epirubicin—prostate cancer	5.43e-05	0.000516	CcSEcCtD
Crizotinib—Fatigue—Mitoxantrone—prostate cancer	5.42e-05	0.000516	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	5.42e-05	0.000515	CcSEcCtD
Crizotinib—Vomiting—Goserelin—prostate cancer	5.41e-05	0.000515	CcSEcCtD
Crizotinib—Constipation—Mitoxantrone—prostate cancer	5.37e-05	0.000511	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—prostate cancer	5.37e-05	0.000511	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—prostate cancer	5.37e-05	0.000511	CcSEcCtD
Crizotinib—Rash—Goserelin—prostate cancer	5.36e-05	0.000511	CcSEcCtD
Crizotinib—Dermatitis—Goserelin—prostate cancer	5.36e-05	0.00051	CcSEcCtD
Crizotinib—Vomiting—Conjugated Estrogens—prostate cancer	5.36e-05	0.00051	CcSEcCtD
Crizotinib—Mediastinal disorder—Capecitabine—prostate cancer	5.34e-05	0.000508	CcSEcCtD
Crizotinib—Body temperature increased—Estradiol—prostate cancer	5.33e-05	0.000507	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—prostate cancer	5.33e-05	0.000507	CcSEcCtD
Crizotinib—Malnutrition—Docetaxel—prostate cancer	5.32e-05	0.000507	CcSEcCtD
Crizotinib—Rash—Conjugated Estrogens—prostate cancer	5.31e-05	0.000506	CcSEcCtD
Crizotinib—Dermatitis—Conjugated Estrogens—prostate cancer	5.31e-05	0.000505	CcSEcCtD
Crizotinib—Arrhythmia—Capecitabine—prostate cancer	5.29e-05	0.000503	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—prostate cancer	5.26e-05	0.0005	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—prostate cancer	5.26e-05	0.0005	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—prostate cancer	5.21e-05	0.000496	CcSEcCtD
Crizotinib—Infection—Etoposide—prostate cancer	5.19e-05	0.000494	CcSEcCtD
Crizotinib—Malnutrition—Capecitabine—prostate cancer	5.15e-05	0.000491	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—prostate cancer	5.08e-05	0.000483	CcSEcCtD
Crizotinib—ABL1—Levorphanol—Estradiol—prostate cancer	5.07e-05	0.0195	CbGdCrCtD
Crizotinib—Nausea—Goserelin—prostate cancer	5.05e-05	0.000481	CcSEcCtD
Crizotinib—Dysgeusia—Capecitabine—prostate cancer	5.05e-05	0.00048	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—prostate cancer	5.02e-05	0.000478	CcSEcCtD
Crizotinib—Nausea—Conjugated Estrogens—prostate cancer	5.01e-05	0.000476	CcSEcCtD
Crizotinib—Body temperature increased—Mitoxantrone—prostate cancer	4.97e-05	0.000473	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	4.97e-05	0.000473	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—prostate cancer	4.93e-05	0.000469	CcSEcCtD
Crizotinib—Anaemia—Docetaxel—prostate cancer	4.92e-05	0.000468	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	4.86e-05	0.000463	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—prostate cancer	4.86e-05	0.000463	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—prostate cancer	4.86e-05	0.000462	CcSEcCtD
Crizotinib—Asthenia—Estradiol—prostate cancer	4.84e-05	0.000461	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—prostate cancer	4.82e-05	0.000459	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—prostate cancer	4.79e-05	0.000456	CcSEcCtD
Crizotinib—ABCB1—seminal vesicle—prostate cancer	4.78e-05	0.000565	CbGeAlD
Crizotinib—Syncope—Docetaxel—prostate cancer	4.77e-05	0.000454	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—prostate cancer	4.76e-05	0.000453	CcSEcCtD
Crizotinib—Anaemia—Capecitabine—prostate cancer	4.76e-05	0.000453	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—prostate cancer	4.71e-05	0.000448	CcSEcCtD
Crizotinib—Paraesthesia—Etoposide—prostate cancer	4.69e-05	0.000447	CcSEcCtD
Crizotinib—Loss of consciousness—Docetaxel—prostate cancer	4.68e-05	0.000445	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—prostate cancer	4.66e-05	0.000444	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—prostate cancer	4.66e-05	0.000444	CcSEcCtD
Crizotinib—Syncope—Capecitabine—prostate cancer	4.62e-05	0.00044	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—prostate cancer	4.62e-05	0.00044	CcSEcCtD
Crizotinib—Diarrhoea—Estradiol—prostate cancer	4.61e-05	0.000439	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—prostate cancer	4.61e-05	0.000439	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—prostate cancer	4.59e-05	0.000437	CcSEcCtD
Crizotinib—Infestation—Epirubicin—prostate cancer	4.59e-05	0.000437	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—prostate cancer	4.59e-05	0.000437	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—prostate cancer	4.54e-05	0.000432	CcSEcCtD
Crizotinib—Loss of consciousness—Capecitabine—prostate cancer	4.53e-05	0.000431	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—prostate cancer	4.51e-05	0.00043	CcSEcCtD
Crizotinib—Asthenia—Mitoxantrone—prostate cancer	4.51e-05	0.000429	CcSEcCtD
Crizotinib—Fatigue—Etoposide—prostate cancer	4.51e-05	0.000429	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—prostate cancer	4.5e-05	0.000429	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.5e-05	0.000428	CcSEcCtD
Crizotinib—Constipation—Etoposide—prostate cancer	4.47e-05	0.000425	CcSEcCtD
Crizotinib—Dizziness—Estradiol—prostate cancer	4.46e-05	0.000424	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—prostate cancer	4.46e-05	0.000424	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—prostate cancer	4.43e-05	0.000422	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.36e-05	0.000415	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—prostate cancer	4.34e-05	0.000414	CcSEcCtD
Crizotinib—Oedema—Docetaxel—prostate cancer	4.34e-05	0.000413	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—prostate cancer	4.33e-05	0.000412	CcSEcCtD
Crizotinib—Infection—Docetaxel—prostate cancer	4.32e-05	0.000411	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—prostate cancer	4.31e-05	0.000411	CcSEcCtD
Crizotinib—Diarrhoea—Mitoxantrone—prostate cancer	4.3e-05	0.000409	CcSEcCtD
Crizotinib—Vomiting—Estradiol—prostate cancer	4.29e-05	0.000408	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—prostate cancer	4.28e-05	0.000407	CcSEcCtD
Crizotinib—Shock—Docetaxel—prostate cancer	4.27e-05	0.000407	CcSEcCtD
Crizotinib—Nervous system disorder—Docetaxel—prostate cancer	4.26e-05	0.000405	CcSEcCtD
Crizotinib—Rash—Estradiol—prostate cancer	4.25e-05	0.000405	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—prostate cancer	4.25e-05	0.000405	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—prostate cancer	4.25e-05	0.000405	CcSEcCtD
Crizotinib—Dermatitis—Estradiol—prostate cancer	4.25e-05	0.000404	CcSEcCtD
Crizotinib—Anaemia—Prednisone—prostate cancer	4.24e-05	0.000404	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—prostate cancer	4.22e-05	0.000402	CcSEcCtD
Crizotinib—Oedema—Capecitabine—prostate cancer	4.21e-05	0.0004	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—prostate cancer	4.2e-05	0.0004	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—prostate cancer	4.19e-05	0.0161	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—prostate cancer	4.19e-05	0.0161	CbGdCrCtD
Crizotinib—Infection—Capecitabine—prostate cancer	4.18e-05	0.000398	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—prostate cancer	4.17e-05	0.000397	CcSEcCtD
Crizotinib—ABCB1—epithelium—prostate cancer	4.15e-05	0.000491	CbGeAlD
Crizotinib—Shock—Capecitabine—prostate cancer	4.14e-05	0.000394	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—prostate cancer	4.13e-05	0.000393	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—prostate cancer	4.12e-05	0.000393	CcSEcCtD
Crizotinib—Syncope—Prednisone—prostate cancer	4.12e-05	0.000392	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—prostate cancer	4.1e-05	0.000391	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—prostate cancer	4.09e-05	0.000389	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—prostate cancer	4.07e-05	0.000388	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—prostate cancer	4.06e-05	0.000387	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—prostate cancer	4.04e-05	0.000385	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—prostate cancer	4.03e-05	0.000384	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—prostate cancer	4.02e-05	0.000383	CcSEcCtD
Crizotinib—Nausea—Estradiol—prostate cancer	4.01e-05	0.000381	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—prostate cancer	4e-05	0.00038	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—prostate cancer	3.97e-05	0.000378	CcSEcCtD
Crizotinib—Rash—Mitoxantrone—prostate cancer	3.96e-05	0.000377	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—prostate cancer	3.96e-05	0.000377	CcSEcCtD
Crizotinib—Paraesthesia—Docetaxel—prostate cancer	3.9e-05	0.000371	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—prostate cancer	3.88e-05	0.00037	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.88e-05	0.000369	CcSEcCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—prostate cancer	3.88e-05	0.0149	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—prostate cancer	3.88e-05	0.0149	CbGdCrCtD
Crizotinib—Dyspnoea—Docetaxel—prostate cancer	3.87e-05	0.000369	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—prostate cancer	3.85e-05	0.000367	CcSEcCtD
Crizotinib—ABCB1—renal system—prostate cancer	3.85e-05	0.000455	CbGeAlD
Crizotinib—Cardiac disorder—Epirubicin—prostate cancer	3.83e-05	0.000364	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—prostate cancer	3.82e-05	0.000364	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—prostate cancer	3.8e-05	0.000361	CcSEcCtD
Crizotinib—ABCB1—urethra—prostate cancer	3.78e-05	0.000447	CbGeAlD
Crizotinib—Paraesthesia—Capecitabine—prostate cancer	3.78e-05	0.000359	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—prostate cancer	3.78e-05	0.000359	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—prostate cancer	3.77e-05	0.000359	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—prostate cancer	3.76e-05	0.000358	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—prostate cancer	3.75e-05	0.000357	CcSEcCtD
Crizotinib—Asthenia—Etoposide—prostate cancer	3.75e-05	0.000357	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—prostate cancer	3.75e-05	0.000357	CcSEcCtD
Crizotinib—Oedema—Prednisone—prostate cancer	3.75e-05	0.000357	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—prostate cancer	3.75e-05	0.000356	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—prostate cancer	3.74e-05	0.000356	CcSEcCtD
Crizotinib—Nausea—Mitoxantrone—prostate cancer	3.73e-05	0.000355	CcSEcCtD
Crizotinib—Infection—Prednisone—prostate cancer	3.72e-05	0.000354	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—prostate cancer	3.72e-05	0.000354	CcSEcCtD
Crizotinib—Constipation—Docetaxel—prostate cancer	3.71e-05	0.000354	CcSEcCtD
Crizotinib—Dyspepsia—Capecitabine—prostate cancer	3.7e-05	0.000352	CcSEcCtD
Crizotinib—Shock—Prednisone—prostate cancer	3.69e-05	0.000351	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—prostate cancer	3.68e-05	0.000351	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—prostate cancer	3.68e-05	0.00035	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—prostate cancer	3.67e-05	0.00035	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—prostate cancer	3.66e-05	0.000348	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—prostate cancer	3.64e-05	0.000346	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Capecitabine—prostate cancer	3.63e-05	0.000346	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—prostate cancer	3.63e-05	0.000345	CcSEcCtD
Crizotinib—Constipation—Capecitabine—prostate cancer	3.6e-05	0.000342	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—prostate cancer	3.59e-05	0.000342	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—prostate cancer	3.58e-05	0.00034	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—prostate cancer	3.57e-05	0.000339	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—prostate cancer	3.54e-05	0.000337	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—prostate cancer	3.52e-05	0.0135	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	3.52e-05	0.0135	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	3.52e-05	0.0135	CbGdCrCtD
Crizotinib—Dysgeusia—Epirubicin—prostate cancer	3.52e-05	0.000335	CcSEcCtD
Crizotinib—Dizziness—Etoposide—prostate cancer	3.46e-05	0.000329	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—prostate cancer	3.44e-05	0.000327	CcSEcCtD
Crizotinib—Body temperature increased—Docetaxel—prostate cancer	3.43e-05	0.000327	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—prostate cancer	3.41e-05	0.000324	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—prostate cancer	3.38e-05	0.000322	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—prostate cancer	3.36e-05	0.00032	CcSEcCtD
Crizotinib—Body temperature increased—Capecitabine—prostate cancer	3.32e-05	0.000316	CcSEcCtD
Crizotinib—Vomiting—Etoposide—prostate cancer	3.32e-05	0.000316	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—prostate cancer	3.32e-05	0.000316	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—prostate cancer	3.32e-05	0.000316	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—prostate cancer	3.3e-05	0.000314	CcSEcCtD
Crizotinib—Rash—Etoposide—prostate cancer	3.3e-05	0.000314	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—prostate cancer	3.29e-05	0.000313	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—prostate cancer	3.28e-05	0.0126	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—prostate cancer	3.28e-05	0.0126	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—prostate cancer	3.28e-05	0.0126	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	3.26e-05	0.0125	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	3.26e-05	0.0125	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	3.26e-05	0.0125	CbGdCrCtD
Crizotinib—Decreased appetite—Prednisone—prostate cancer	3.26e-05	0.00031	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—prostate cancer	3.25e-05	0.00031	CcSEcCtD
Crizotinib—Fatigue—Prednisone—prostate cancer	3.23e-05	0.000307	CcSEcCtD
Crizotinib—Syncope—Epirubicin—prostate cancer	3.22e-05	0.000306	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—prostate cancer	3.21e-05	0.000306	CcSEcCtD
Crizotinib—Constipation—Prednisone—prostate cancer	3.2e-05	0.000305	CcSEcCtD
Crizotinib—Loss of consciousness—Epirubicin—prostate cancer	3.16e-05	0.0003	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—prostate cancer	3.13e-05	0.000298	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—prostate cancer	3.12e-05	0.000297	CcSEcCtD
Crizotinib—Nausea—Etoposide—prostate cancer	3.1e-05	0.000296	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—prostate cancer	3.07e-05	0.000292	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.04e-05	0.000289	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—prostate cancer	3.03e-05	0.0117	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—prostate cancer	3.03e-05	0.0117	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—prostate cancer	3.03e-05	0.0117	CbGdCrCtD
Crizotinib—Asthenia—Capecitabine—prostate cancer	3.02e-05	0.000287	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—prostate cancer	2.98e-05	0.000284	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—prostate cancer	2.97e-05	0.000283	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—prostate cancer	2.97e-05	0.000283	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—prostate cancer	2.96e-05	0.000282	CcSEcCtD
Crizotinib—Oedema—Epirubicin—prostate cancer	2.93e-05	0.000279	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—prostate cancer	2.92e-05	0.000278	CcSEcCtD
Crizotinib—ABCB1—bone marrow—prostate cancer	2.91e-05	0.000344	CbGeAlD
Crizotinib—Infection—Epirubicin—prostate cancer	2.91e-05	0.000277	CcSEcCtD
Crizotinib—Shock—Epirubicin—prostate cancer	2.88e-05	0.000274	CcSEcCtD
Crizotinib—Diarrhoea—Capecitabine—prostate cancer	2.88e-05	0.000274	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—prostate cancer	2.87e-05	0.000273	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—prostate cancer	2.87e-05	0.000273	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—prostate cancer	2.85e-05	0.000271	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.81e-05	0.000267	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—prostate cancer	2.81e-05	0.0108	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—prostate cancer	2.81e-05	0.0108	CbGdCrCtD
Crizotinib—Dizziness—Capecitabine—prostate cancer	2.78e-05	0.000265	CcSEcCtD
Crizotinib—Vomiting—Docetaxel—prostate cancer	2.76e-05	0.000263	CcSEcCtD
Crizotinib—Rash—Docetaxel—prostate cancer	2.74e-05	0.000261	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—prostate cancer	2.74e-05	0.00026	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—prostate cancer	2.71e-05	0.000258	CcSEcCtD
Crizotinib—Infection—Doxorubicin—prostate cancer	2.69e-05	0.000256	CcSEcCtD
Crizotinib—Asthenia—Prednisone—prostate cancer	2.69e-05	0.000256	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—prostate cancer	2.67e-05	0.000255	CcSEcCtD
Crizotinib—Shock—Doxorubicin—prostate cancer	2.67e-05	0.000254	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—prostate cancer	2.66e-05	0.000253	CcSEcCtD
Crizotinib—Rash—Capecitabine—prostate cancer	2.65e-05	0.000252	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—prostate cancer	2.65e-05	0.000252	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—prostate cancer	2.63e-05	0.000251	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—prostate cancer	2.63e-05	0.00025	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—prostate cancer	2.61e-05	0.000249	CcSEcCtD
Crizotinib—Nausea—Docetaxel—prostate cancer	2.58e-05	0.000246	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—prostate cancer	2.58e-05	0.000245	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—prostate cancer	2.56e-05	0.000244	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—prostate cancer	2.55e-05	0.000242	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.53e-05	0.000241	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—prostate cancer	2.53e-05	0.00024	CcSEcCtD
Crizotinib—Constipation—Epirubicin—prostate cancer	2.51e-05	0.000238	CcSEcCtD
Crizotinib—Nausea—Capecitabine—prostate cancer	2.5e-05	0.000238	CcSEcCtD
Crizotinib—ABCB1—testis—prostate cancer	2.49e-05	0.000294	CbGeAlD
Crizotinib—Dizziness—Prednisone—prostate cancer	2.48e-05	0.000236	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—prostate cancer	2.43e-05	0.000232	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—prostate cancer	2.42e-05	0.00023	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—prostate cancer	2.39e-05	0.000227	CcSEcCtD
Crizotinib—Vomiting—Prednisone—prostate cancer	2.38e-05	0.000227	CcSEcCtD
Crizotinib—Rash—Prednisone—prostate cancer	2.36e-05	0.000225	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—prostate cancer	2.36e-05	0.000225	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—prostate cancer	2.36e-05	0.000224	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.34e-05	0.000223	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—prostate cancer	2.34e-05	0.000222	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—prostate cancer	2.32e-05	0.000221	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—prostate cancer	2.32e-05	0.00022	CcSEcCtD
Crizotinib—Nausea—Prednisone—prostate cancer	2.23e-05	0.000212	CcSEcCtD
Crizotinib—Body temperature increased—Doxorubicin—prostate cancer	2.14e-05	0.000204	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—prostate cancer	2.1e-05	0.0002	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—prostate cancer	2e-05	0.000191	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—prostate cancer	1.95e-05	0.000185	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—prostate cancer	1.94e-05	0.000184	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—prostate cancer	1.86e-05	0.000177	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—prostate cancer	1.85e-05	0.000177	CcSEcCtD
Crizotinib—Rash—Epirubicin—prostate cancer	1.85e-05	0.000176	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—prostate cancer	1.85e-05	0.000176	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—prostate cancer	1.81e-05	0.00695	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—prostate cancer	1.81e-05	0.00695	CbGdCrCtD
Crizotinib—ABCB1—lymph node—prostate cancer	1.8e-05	0.000213	CbGeAlD
Crizotinib—Dizziness—Doxorubicin—prostate cancer	1.79e-05	0.000171	CcSEcCtD
Crizotinib—Nausea—Epirubicin—prostate cancer	1.74e-05	0.000166	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—prostate cancer	1.72e-05	0.000164	CcSEcCtD
Crizotinib—Rash—Doxorubicin—prostate cancer	1.71e-05	0.000163	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—prostate cancer	1.71e-05	0.000163	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—prostate cancer	1.61e-05	0.000153	CcSEcCtD
Crizotinib—PTK2B—Signaling Pathways—IL6—prostate cancer	2.58e-07	1.74e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—prostate cancer	2.57e-07	1.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—prostate cancer	2.57e-07	1.74e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—prostate cancer	2.57e-07	1.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—prostate cancer	2.57e-07	1.74e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—prostate cancer	2.55e-07	1.73e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—prostate cancer	2.55e-07	1.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—prostate cancer	2.55e-07	1.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GSK3B—prostate cancer	2.54e-07	1.72e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—prostate cancer	2.53e-07	1.71e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—prostate cancer	2.52e-07	1.71e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—prostate cancer	2.52e-07	1.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—prostate cancer	2.52e-07	1.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HPGDS—prostate cancer	2.51e-07	1.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—prostate cancer	2.51e-07	1.7e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—prostate cancer	2.51e-07	1.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—prostate cancer	2.5e-07	1.69e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—prostate cancer	2.5e-07	1.69e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—prostate cancer	2.5e-07	1.69e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.5e-07	1.69e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—prostate cancer	2.5e-07	1.69e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—prostate cancer	2.49e-07	1.68e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—prostate cancer	2.49e-07	1.68e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—prostate cancer	2.48e-07	1.68e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—prostate cancer	2.48e-07	1.68e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—prostate cancer	2.48e-07	1.68e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—prostate cancer	2.48e-07	1.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—prostate cancer	2.48e-07	1.68e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LPL—prostate cancer	2.47e-07	1.67e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—prostate cancer	2.47e-07	1.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—prostate cancer	2.47e-07	1.67e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—prostate cancer	2.47e-07	1.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—prostate cancer	2.45e-07	1.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—prostate cancer	2.45e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—prostate cancer	2.45e-07	1.66e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—prostate cancer	2.44e-07	1.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACHE—prostate cancer	2.44e-07	1.65e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—prostate cancer	2.43e-07	1.64e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—prostate cancer	2.43e-07	1.64e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—prostate cancer	2.42e-07	1.64e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—prostate cancer	2.42e-07	1.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—prostate cancer	2.42e-07	1.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—prostate cancer	2.42e-07	1.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—prostate cancer	2.41e-07	1.63e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—prostate cancer	2.41e-07	1.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JAK2—prostate cancer	2.41e-07	1.63e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.41e-07	1.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—prostate cancer	2.41e-07	1.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—prostate cancer	2.4e-07	1.62e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—prostate cancer	2.39e-07	1.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—prostate cancer	2.39e-07	1.62e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—prostate cancer	2.39e-07	1.62e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—prostate cancer	2.39e-07	1.61e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—prostate cancer	2.38e-07	1.61e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—prostate cancer	2.37e-07	1.6e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—prostate cancer	2.36e-07	1.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—prostate cancer	2.35e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—prostate cancer	2.35e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—prostate cancer	2.35e-07	1.59e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—prostate cancer	2.35e-07	1.59e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.35e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—prostate cancer	2.34e-07	1.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K1—prostate cancer	2.34e-07	1.58e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—prostate cancer	2.34e-07	1.58e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—prostate cancer	2.33e-07	1.58e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PRKACB—prostate cancer	2.33e-07	1.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—prostate cancer	2.33e-07	1.57e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—prostate cancer	2.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—prostate cancer	2.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—prostate cancer	2.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—prostate cancer	2.32e-07	1.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.31e-07	1.56e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—prostate cancer	2.3e-07	1.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—prostate cancer	2.3e-07	1.56e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—prostate cancer	2.3e-07	1.56e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—prostate cancer	2.3e-07	1.55e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—prostate cancer	2.29e-07	1.55e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—prostate cancer	2.29e-07	1.55e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—prostate cancer	2.28e-07	1.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—prostate cancer	2.28e-07	1.54e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—prostate cancer	2.27e-07	1.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—prostate cancer	2.27e-07	1.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—prostate cancer	2.26e-07	1.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—prostate cancer	2.26e-07	1.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—prostate cancer	2.24e-07	1.52e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—prostate cancer	2.24e-07	1.51e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—prostate cancer	2.24e-07	1.51e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—prostate cancer	2.23e-07	1.51e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—prostate cancer	2.23e-07	1.51e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—prostate cancer	2.21e-07	1.5e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—prostate cancer	2.21e-07	1.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—prostate cancer	2.2e-07	1.49e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—prostate cancer	2.2e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—prostate cancer	2.2e-07	1.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOA2—prostate cancer	2.2e-07	1.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—prostate cancer	2.2e-07	1.49e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARA—prostate cancer	2.19e-07	1.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—prostate cancer	2.18e-07	1.48e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	2.18e-07	1.48e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—prostate cancer	2.18e-07	1.48e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—prostate cancer	2.17e-07	1.47e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—prostate cancer	2.17e-07	1.47e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—prostate cancer	2.16e-07	1.46e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—prostate cancer	2.16e-07	1.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—prostate cancer	2.15e-07	1.46e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—prostate cancer	2.15e-07	1.46e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	2.15e-07	1.45e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—prostate cancer	2.14e-07	1.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JAK2—prostate cancer	2.13e-07	1.44e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—prostate cancer	2.11e-07	1.43e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—prostate cancer	2.1e-07	1.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—prostate cancer	2.1e-07	1.42e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.1e-07	1.42e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—prostate cancer	2.1e-07	1.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—prostate cancer	2.1e-07	1.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—prostate cancer	2.08e-07	1.41e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—prostate cancer	2.08e-07	1.41e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—prostate cancer	2.08e-07	1.41e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—prostate cancer	2.07e-07	1.4e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—prostate cancer	2.06e-07	1.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—prostate cancer	2.06e-07	1.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—prostate cancer	2.05e-07	1.39e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—prostate cancer	2.05e-07	1.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—prostate cancer	2.05e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.05e-07	1.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—prostate cancer	2.04e-07	1.38e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—prostate cancer	2.03e-07	1.38e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—prostate cancer	2.03e-07	1.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	2.03e-07	1.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—prostate cancer	2.03e-07	1.37e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—prostate cancer	2.03e-07	1.37e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—prostate cancer	2.02e-07	1.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—prostate cancer	2.02e-07	1.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—prostate cancer	2.02e-07	1.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—prostate cancer	2.01e-07	1.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—prostate cancer	2.01e-07	1.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—prostate cancer	2e-07	1.35e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TH—prostate cancer	2e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—prostate cancer	1.99e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—prostate cancer	1.99e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	1.98e-07	1.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—prostate cancer	1.98e-07	1.34e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—prostate cancer	1.96e-07	1.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—prostate cancer	1.95e-07	1.32e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.94e-07	1.31e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—prostate cancer	1.92e-07	1.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—prostate cancer	1.92e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—prostate cancer	1.91e-07	1.29e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—prostate cancer	1.91e-07	1.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—prostate cancer	1.9e-07	1.29e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.9e-07	1.29e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—prostate cancer	1.89e-07	1.28e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—prostate cancer	1.89e-07	1.28e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—prostate cancer	1.88e-07	1.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GGT1—prostate cancer	1.88e-07	1.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—prostate cancer	1.88e-07	1.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—prostate cancer	1.87e-07	1.27e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.87e-07	1.27e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—prostate cancer	1.87e-07	1.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—prostate cancer	1.86e-07	1.26e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—prostate cancer	1.86e-07	1.26e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—prostate cancer	1.86e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—prostate cancer	1.86e-07	1.26e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—prostate cancer	1.85e-07	1.25e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.85e-07	1.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—prostate cancer	1.84e-07	1.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—prostate cancer	1.84e-07	1.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.83e-07	1.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—prostate cancer	1.82e-07	1.23e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—prostate cancer	1.8e-07	1.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—prostate cancer	1.79e-07	1.21e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—prostate cancer	1.77e-07	1.2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—prostate cancer	1.77e-07	1.2e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—prostate cancer	1.77e-07	1.2e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—prostate cancer	1.77e-07	1.19e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—prostate cancer	1.77e-07	1.19e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—prostate cancer	1.76e-07	1.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RXRA—prostate cancer	1.76e-07	1.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—prostate cancer	1.76e-07	1.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—prostate cancer	1.76e-07	1.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—prostate cancer	1.75e-07	1.19e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—prostate cancer	1.74e-07	1.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—prostate cancer	1.74e-07	1.17e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—prostate cancer	1.72e-07	1.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—prostate cancer	1.7e-07	1.15e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—prostate cancer	1.7e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—prostate cancer	1.69e-07	1.15e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.69e-07	1.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—prostate cancer	1.67e-07	1.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.66e-07	1.13e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—prostate cancer	1.65e-07	1.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.65e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—prostate cancer	1.64e-07	1.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—prostate cancer	1.64e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—prostate cancer	1.64e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—prostate cancer	1.63e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—prostate cancer	1.61e-07	1.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—prostate cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—prostate cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—prostate cancer	1.57e-07	1.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—prostate cancer	1.57e-07	1.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—prostate cancer	1.57e-07	1.06e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—prostate cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—prostate cancer	1.55e-07	1.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.55e-07	1.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—prostate cancer	1.54e-07	1.04e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LPL—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—prostate cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—prostate cancer	1.51e-07	1.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.47e-07	9.96e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.46e-07	9.88e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—prostate cancer	1.46e-07	9.85e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—prostate cancer	1.45e-07	9.83e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—prostate cancer	1.44e-07	9.75e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—prostate cancer	1.43e-07	9.71e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—prostate cancer	1.42e-07	9.63e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—prostate cancer	1.42e-07	9.62e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—prostate cancer	1.41e-07	9.55e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	1.4e-07	9.45e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—prostate cancer	1.39e-07	9.41e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—prostate cancer	1.37e-07	9.29e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—prostate cancer	1.35e-07	9.14e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARA—prostate cancer	1.35e-07	9.11e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—prostate cancer	1.35e-07	9.1e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—prostate cancer	1.3e-07	8.81e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—prostate cancer	1.27e-07	8.57e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—prostate cancer	1.24e-07	8.39e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—prostate cancer	1.24e-07	8.36e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—prostate cancer	1.24e-07	8.36e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—prostate cancer	1.2e-07	8.09e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—prostate cancer	1.18e-07	8e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.16e-07	7.84e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.15e-07	7.8e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—prostate cancer	1.14e-07	7.72e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—prostate cancer	1.09e-07	7.4e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—prostate cancer	1.09e-07	7.39e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—prostate cancer	1.07e-07	7.23e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.01e-07	6.86e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—prostate cancer	1.01e-07	6.83e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—prostate cancer	9.58e-08	6.48e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—prostate cancer	9.47e-08	6.4e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.84e-08	5.98e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—prostate cancer	8.76e-08	5.92e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—prostate cancer	8.75e-08	5.92e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—prostate cancer	7.64e-08	5.17e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—prostate cancer	7.28e-08	4.93e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—prostate cancer	7.14e-08	4.83e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.39e-08	3.65e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—prostate cancer	4.4e-08	2.98e-07	CbGpPWpGaD
